{"disease":{"id":"recurrent-or-metastatic-cancer","name":"recurrent or metastatic cancer"},"drugs":{"marketed":[{"drug_id":"tisotumab-vedotin","indication_name":"Recurrent or metastatic cervical cancer with disease progression on or after chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tivdak","generic_name":"tisotumab-vedotin","company_name":"SEAGEN","drug_phase":"marketed","molecular_target":"Tissue factor","drug_class":"Antibody-drug conjugate","quality_score":10,"revenue":"147","mechanism":"Tisotumab vedotin is a tissue factor (TF)-directed antibody drug conjugate that targets and disrupts microtubule networks in cancer cells."},{"drug_id":"tisotumab","indication_name":"recurrent or metastatic cervical cancer with disease progression on or after chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tivdak","generic_name":"TISOTUMAB","company_name":"Seagen","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":64,"revenue":"147","mechanism":"Tivdak works by binding to a specific target on cancer cells, triggering an immune response to destroy the cancer."},{"drug_id":"tivdak","indication_name":"Treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tisotumab Vedotin","generic_name":"tivdak","company_name":"SEAGEN","drug_phase":"marketed","molecular_target":"Tissue factor","drug_class":"Antibody-Drug Conjugate (ADC)","quality_score":10,"revenue":"147","mechanism":""},{"drug_id":"bevacizumab-maly","indication_name":"Persistent, Recurrent, or Metastatic Cervical Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ALYMSYS","generic_name":"BEVACIZUMAB-MALY","company_name":"AMNEAL PHARMS LLC","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05838066","title":"Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":880,"lead_sponsor_name":"Shanghai JMT-Bio Inc.","has_results":false},{"nct_id":"NCT06155422","title":"A Prospective Real-world Study of Cadonilimab in Patients With Recurrent or Metastatic Cervical Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":670,"lead_sponsor_name":"Gang Chen (101199)","has_results":false},{"nct_id":"NCT03257267","title":"Study of Cemiplimab in Adults With Cervical Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":608,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT03315364","title":"Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":549,"lead_sponsor_name":"Daehwa Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05798819","title":"A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":424,"lead_sponsor_name":"Guangzhou Gloria Biosciences Co., Ltd.","has_results":false},{"nct_id":"NCT07406542","title":"A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":400,"lead_sponsor_name":"CSPC Megalith Biopharmaceutical Co.,Ltd.","has_results":false},{"nct_id":"NCT02625623","title":"Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":371,"lead_sponsor_name":"EMD Serono Research & Development Institute, Inc.","has_results":true},{"nct_id":"NCT05715840","title":"Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":368,"lead_sponsor_name":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","has_results":false},{"nct_id":"NCT03924986","title":"Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":263,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT04680988","title":"A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":194,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT01283204","title":"Trial of 4-regimen (SP, FL/Tax, FL/Doc, FOLFOX) in Patients With Recurrent or Metastatic Gastric Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":180,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT06892431","title":"JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":150,"lead_sponsor_name":"Shanghai JMT-Bio Inc.","has_results":false},{"nct_id":"NCT05136196","title":"BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03109249","title":"Pharmacokinetic Study of SPARC1613 and reference1613 in Subjects With Locally Recurrent or Metastatic Breast Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":142,"lead_sponsor_name":"Sun Pharma Advanced Research Company Limited","has_results":false},{"nct_id":"NCT04623333","title":"A Study of TQB2450 Injection in Subjects With PD-L1 Positive Recurrent or Metastatic Cervical Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT03326102","title":"Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"Daehwa Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT07121244","title":"A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":62,"lead_sponsor_name":"Radionetics Oncology","has_results":false},{"nct_id":"NCT05990543","title":"Combination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":59,"lead_sponsor_name":"Korea University Anam Hospital","has_results":false},{"nct_id":"NCT03728361","title":"Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":55,"lead_sponsor_name":"Dwight Owen","has_results":false},{"nct_id":"NCT04868708","title":"A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Akeso","has_results":false},{"nct_id":"NCT06728852","title":"Efficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Patients: a Single-arm, Prospective, Open-label Phase II Clinical Study","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":32,"lead_sponsor_name":"Li-kun Chen","has_results":false},{"nct_id":"NCT06751277","title":"QL1706 Combined with Chemotherapy in the Treatment of Recurrent or Metastatic Endometrial Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":26,"lead_sponsor_name":"xiang yang","has_results":false},{"nct_id":"NCT04713046","title":"Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":24,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","has_results":false},{"nct_id":"NCT01254617","title":"Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01316757","title":"Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Fox Chase Cancer Center","has_results":false},{"nct_id":"NCT06982053","title":"[68Ga]Ga-GZP PET for Early Response Prediction in Colorectal Cancer During Neoadjuvant Therapy","phase":"NA","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT06625515","title":"First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":17,"lead_sponsor_name":"Accent Therapeutics","has_results":false},{"nct_id":"NCT00470496","title":"Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT07081984","title":"Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"Therorna","has_results":false},{"nct_id":"NCT05559177","title":"An Open, Dose-escalation Clinical Study of Chimeric Exosomal Tumor Vaccines for Recurrent or Metastatic Bladder Cancer","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":9,"lead_sponsor_name":"Shanghai Pudong Hospital","has_results":false},{"nct_id":"NCT02035527","title":"Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT04906382","title":"Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer","phase":"EARLY_PHASE1","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Floor Backes, MD","has_results":false}],"total":32},"guidelines":[],"source":"Drug Landscape verified database"}